G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genomed SA
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Free Cash Flow
zł1.8m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Free Cash Flow
zł15.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Free Cash Flow
-zł716.1k
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
4%
B
Bioton SA
WSE:BIO
Free Cash Flow
zł13.2m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Free Cash Flow
-zł7.1m
CAGR 3-Years
-72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Free Cash Flow
-zł101.7m
CAGR 3-Years
-373%
CAGR 5-Years
N/A
CAGR 10-Years
-27%
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Free Cash Flow?
Free Cash Flow
1.8m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Free Cash Flow amounts to 1.8m PLN.

What is Genomed SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
26%

The average annual Free Cash Flow growth rates for Genomed SA have been 26% over the past three years .

Back to Top